Tianlong Showcases Cutting-Edge Products and Innovative Molecular Diagnostic Solutions

Tianlong Science and Technology (Shaanxi, China) is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023. The company is also highlighting its classic integrated PCR lab solution and its brand new product - Panall 8000 All-in-One Molecular Diagnosis System at the show. The revolutionary Panall 8000 All-in-One Molecular Diagnosis System seamlessly integrates various diagnostic stages, setting new standards for efficiency and accuracy in the field of molecular diagnostics.

Tianlong is also exhibiting the RBT320 Agglutination Automated Detection System which is intended for the detection of Brucellosis based on the Rose Bengal Test (RBT) method. Designed for automating laboratory workflow, Tianlong RBT320 integrates various functions, including automatic sample loading, sample mixing, photographing, AI image recognition, and result interpretation. With optimized efficiency, RBT320 can process 320 samples per hour and is suitable for large-scale screening of Brucella antibodies. Tianlong RBT320 is highly automated and can empower labs with maximum efficiency and effectively avoid human errors, while the use of the RBT method can also be cost-effective for labs.

At MEDICA 2023, Tianlong is also presenting the iGeneCase 1600 Diagnostics-in-a-Suitcase, and PANA 9600X Automated Nucleic Acid Workstation, as well as a variety of products and compatible reagents. For instance, Tianlong's solution for nucleic acid detection of influenza virus is designed to identify and differentiate various strains, including Influenza A/B, Influenza C, Influenza A(H1&H3), Influenza A(H1N1), Influenza A(H3N2), and Influenza A(H5N1), as well as multiplex kit for Influenza A/B/Human Adenovirus/2019-nCoV. This comprehensive solution provides a scientific basis for accurate diagnosis and treatment of individuals with symptoms of influenza.

Related Links:
Tianlong Science and Technology